Taprostene

他前列烯

Report date: 2023/04/21 14:28:30
NME

Base Information

Drug NameTaprostene
Drug Alias NameCG-4203SE-63
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid IP receptor agonists
TargetsProstanoid IP receptor
Therapy Area/IndicationsArterial Occlusive DiseasesMyocardial InfarctionCoronary Restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGruenenthal Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGruenenthal Gmbh
Active IndicationsN/A
Inactive IndicationsArterial Occlusive DiseasesMyocardial InfarctionCoronary Restenosis

Other Information

ATC CodeN/A
Related LinksN/A